American Cancer Society Report Identifies Priorities for Survivorship Care

Share this content:
The ACS estimates that by 2026 the number of cancer survivors will grow to 20.3 million.
The ACS estimates that by 2026 the number of cancer survivors will grow to 20.3 million.

As cancer therapies have evolved over the years, survivorship rates have increased, but the lives and experiences of survivors of cancer have only recently begun to be understood. The higher rates of survivorship have coincided with higher costs and shortages of providers. Additionally, many survivors of cancer face long-term risks to health associated with treatment-related and/or patient-specific susceptibilities.1

Alongside these issues, caregiving has also shifted toward more reliance on families or other people in patients' lives, many of whom have other responsibilities and/or face uncertainty in caregiving. The American Cancer Society (ACS) detailed these and other issues, along with a layout of cancer care-related priorities, in a recent report.1

Updated estimates of cancer diagnoses in the United States are not available; at the time of the ACS report, 1.7 million new cancer diagnoses were projected for 2018. Rates are not increasing for men and women; however, population growth and increased longevity are contributing to increasing numbers of cancer diagnoses. 

Continue Reading Below

Increasing Numbers, Changing Demographics

At the time of ACS report, there were approximately 15.5 million survivors of cancer, with survival rates of 17% for those with diagnoses from 20 or more years ago and 67% for diagnoses from 5 or more years ago. Because of demographic trends in the United States, the ACS estimates that by 2026 the number of cancer survivors will grow to 20.3 million, and to 26.1 million by 2040. By 2040, 73% of these survivors are expected to be 65 or older, compared with a rate of 62% in 2016. 

People from racial and ethnic minority groups are also expected to comprise increasing proportions of patients and survivors. Disparities in care have lessened some for older patients from racial and ethnic minority groups, but outcomes remain poor for those younger than 65. Insufficiently insured patients, as well as immigrants and patients from sexual minorities, also have outcomes that reflect greater difficulties in accessing quality care and information. “We need to acknowledge that certain racial and ethnic groups, neighborhoods, and individuals with lower incomes have different (or additional) barriers preventing them from receiving the care they need and from being as healthy as they want to be,” noted the authors.

Childhood cancer survivorship is relatively high, with 5-year survival rates near 85%, but these survivors are often left with disease comorbidities well into adulthood, which are serious, life-threatening, or disabling for many. Health conditions following childhood and adolescent cancers are often treatment sequelae. 

Page 1 of 2
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs